Literature DB >> 11068575

Criteria for evaluating evidence that laboratory abnormalities are associated with the development of venous thromboembolism.

S M Bates1, J S Ginsberg, S E Straus, H Rekers, D L Sackett.   

Abstract

The identification of conditions associated with an increased risk of venous thromboembolism may indicate the need for aggressive prophylaxis during periods of high risk, prolonged anticoagulant therapy after an initial venous thromboembolic episode, the investigation of asymptomatic family members and the avoidance of oral contraceptives. Advances in laboratory medicine have led to the identification and assessment of many proteins responsible for normal hemostasis, and associations between abnormalities in a number of these proteins and venous thromboembolism have been reported. Without the ability to appraise this information critically, physicians may be unable to determine whether or how they should modify their clinical practice. Criteria for determining whether specific laboratory abnormalities have a relationship with venous thromboembolism are proposed here, and one example of the application of these guidelines is provided.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11068575      PMCID: PMC80552     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  40 in total

1.  Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.

Authors:  J Rosing; S Middeldorp; J Curvers; M Christella; L G Thomassen; G A Nicolaes; J C Meijers; B N Bouma; H R Büller; M H Prins; G Tans
Journal:  Lancet       Date:  1999-12-11       Impact factor: 79.321

2.  INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.

Authors:  O EGEBERG
Journal:  Thromb Diath Haemorrh       Date:  1965-06-15

3.  The familial tendency in thrombo-embolic disease.

Authors:  F L JORDAN; A NANDORFF
Journal:  Acta Med Scand       Date:  1956-12-31

4.  Inappropriate use of the cerebrospinal fluid Venereal Disease Research Laboratory (VDRL) test to exclude neurosyphilis.

Authors:  P E Dans; L Cafferty; S E Otter; R J Johnson
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

5.  Problems of spectrum and bias in evaluating the efficacy of diagnostic tests.

Authors:  D F Ransohoff; A R Feinstein
Journal:  N Engl J Med       Date:  1978-10-26       Impact factor: 91.245

6.  Deficiencies of protein C, an inhibitor of blood coagulation.

Authors:  P M Mannucci; S Vigano
Journal:  Lancet       Date:  1982-08-28       Impact factor: 79.321

7.  Antithrombin III in oral contraceptive users and during normotensive pregnancy.

Authors:  G H Weenink; L H Kahlé; R J Lamping; J W ten Cate; P E Treffers
Journal:  Acta Obstet Gynecol Scand       Date:  1984       Impact factor: 3.636

8.  Inappropriate testing for diarrheal diseases in the hospital.

Authors:  D L Siegel; P H Edelstein; I Nachamkin
Journal:  JAMA       Date:  1990-02-16       Impact factor: 56.272

9.  Heparin-induced decrease in circulating antithrombin-III.

Authors:  E Marciniak; J P Gockerman
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

10.  Antithrombin-III transfusion in disseminated intravascular coagulation.

Authors:  H G Schipper; C S Jenkins; L H Kahlé; J W ten Cate
Journal:  Lancet       Date:  1978-04-22       Impact factor: 79.321

View more
  3 in total

1.  Risk factors for thromboembolism: pathophysiology and detection.

Authors:  S Solymoss
Journal:  CMAJ       Date:  2000-10-17       Impact factor: 8.262

2.  Bridging the gaps in evidence based diagnosis.

Authors:  Sharon E Straus
Journal:  BMJ       Date:  2006-08-26

3.  Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey.

Authors:  D Cook; J McMullin; R Hodder; M Heule; J Pinilla; P Dodek; T Stewart
Journal:  Crit Care       Date:  2001-09-26       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.